Can-Fite BioPharma annual revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Can-Fite BioPharma reported $405,000 in revenue for fiscal 2025, a decrease of 39.91% from the previous fiscal year.
View full Can-Fite BioPharma company overview| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $405,000 | −$269,000 | −39.91% |
| 2024 | 2024-12-31 | $674,000 | −$69,000 | −9.29% |
| 2023 | 2023-12-31 | $743,000 | −$67,000 | −8.27% |
| 2022 | 2022-12-31 | $810,000 | −$43,000 | −5.04% |
| 2021 | 2021-12-31 | $853,000 | $90,000 | +11.80% |
| 2020 | 2020-12-31 | $763,000 | −$1.3M | −62.45% |
| 2019 | 2019-12-31 | $2.0M | −$1.8M | −46.81% |
| 2018 | 2018-12-31 | $3.8M | $3.0M | +384.16% |
| 2017 | 2017-12-31 | $789,000 | $624,000 | +378.18% |
| 2016 | 2016-12-31 | $165,000 | — | — |
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2019 | 2019-07-31 | $750,000 | — | — |
Over the last five reported fiscal years, revenue declined from $763,000 to $405,000, a compound annual decline of 11.90%. Can-Fite BioPharma's latest reported quarter, Q2 2019, generated $750,000 in revenue.
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Can-Fite BioPharma source filings ↗